I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 11th December 2012

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

1 Name of Instrument

 (1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 9).

 (2) This Instrument may also be cited as PB 108 of 2012.

2 Commencement

This Instrument commences on 1 January 2013.

3 Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

 Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).

Schedule 1 Amendments

[1]                Schedule 1, entry for Betamethasone

omit:

[2]                Schedule 1, entry for Bicalutamide

omit from the column headed “Responsible Person” for the brand “Cosudex”: SZ substitute: AP

[3]                Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate)

omit from the column headed “Circumstances” for the brands “APO-Clopidogrel”, Clopidogrel Winthrop”, “Iscover” and “Plavix”:

insert in numerical order:

[4]                Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as besilate)

insert in numerical order in the column headed “Circumstances” for the brand “Clovix 75”:

[5]                Schedule 1, entry for Famciclovir in the form Tablet 500 mg [Max Quantity 56; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[6]                Schedule 1, entry for Felodipine in each of the forms: Tablet 2.5 mg (extended release); Tablet 5 mg (extended release); and
Tablet 10 mg (extended release)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[7]                Schedule 1, entry for Fentanyl in the form Transdermal patch 2.063 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[8]                Schedule 1, entry for Fentanyl in the form Transdermal patch 4.125 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[9]                Schedule 1, entry for Fentanyl in the form Transdermal patch 8.25 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[10]            Schedule 1, entry for Fentanyl in the form Transdermal patch 12.375 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[11]            Schedule 1, entry for Fentanyl in the form Transdermal patch 16.5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[12]            Schedule 1, entry for Fluoxetine in the form Capsule 20 mg (as hydrochloride)

omit from the column headed “Brand”: Auscap substitute: Auscap Aspen

[13]            Schedule 1, entry for Lamotrigine in the form Tablet 25 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[14]            Schedule 1, entry for Lamotrigine in the form Tablet 100 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[15]            Schedule 1, entry for Macrogol 3350 in the form Powder for oral solution 510 g

(a) omit:

(b) omit:

(c) omit:

[16]            Schedule 1, entry for Mirtazapine in each of the forms: Tablet 15 mg (orally disintegrating); Tablet 30 mg (orally disintegrating);
and Tablet 45 mg (orally disintegrating)

omit from the column headed “Brand”: Mirtazapine Pfizer substitute: Mirtazapine Dispersible Pfizer

[17]            Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg

(a) omit:

(b) omit:

[18]            Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 500 mg

(a) omit:

(b) omit:

[19]            Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30; Number of Repeats 2]

(a) omit from the column headed “Responsible Person” for the brand “Panto”: NZ substitute: TK

(b) omit from the column headed “Responsible Person” for the brand “Pantoloc”: NH substitute: TE

[20]            Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30; Number of Repeats 5]

(a) omit from the column headed “Responsible Person” for the brand “Panto”: NZ substitute: TK

(b) omit from the column headed “Responsible Person” for the brand “Pantoloc”: NH substitute: TE

[21]            Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 20 mg (as sodium sesquihydrate)

(a) omit from the column headed “Responsible Person” for the brand “Panto”: NZ substitute: TK

(b) omit from the column headed “Responsible Person” for the brand “Pantoloc”: NH substitute: TE

[22]            Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 10 mg (enteric coated)

(a) omit from the column headed “Brand”: Parzole 10 substitute: Parzol 10

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[23]            Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Max Quantity 30; Number of Repeats 2]

(a) omit from the column headed “Brand”: Parzole 20 substitute: Parzol 20

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

(c) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[24]            Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Max Quantity 30; Number of Repeats 5]

(a) omit from the column headed “Brand”: Parzole 20 substitute: Parzol 20

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

(c) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[25]            Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 2]

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[26]            Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 5]

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[27]            Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 2]

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[28]            Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 5]

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[29]            Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 2]

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[30]            Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 5]

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[31]            Schedule 1, entry for Risperidone in the form Tablet 3 mg

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[32]            Schedule 1, entry for Risperidone in the form Tablet 4 mg

(a) omit:

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[33]            Schedule 1, entry for Terbinafine in the form Tablet 250 mg (as hydrochloride)

(a) omit:

(b) omit:

[34]            Schedule 1, entry for Tramadol in the form Capsule containing tramadol hydrochloride 50 mg

(a) omit:

(b) omit:

[35]            Schedule 1, entry for Tramadol

(a) omit:

(b) omit:

(c) omit:

[36]            Schedule 1, entry for Venlafaxine in each of the forms: Capsule (modified release) 75 mg (as hydrochloride); and Capsule (modified release) 150 mg (as hydrochloride)

omit from the column headed “Brand”: STADA Venlafaxine SR substitute: STADA Venlafaxine-SR

[37]            Schedule 3

omit:

[38]            Schedule 3, details relevant to Responsible person code NQ

omit:  Nycomed Pty Ltd  substitute: Takeda Pharmaceuticals Australia Pty Ltd

[39]            Schedule 3

omit:

[40]            Schedule 3, after details relevant to Responsible person code TD

insert:

[41]            Schedule 4, Part 1, entry for Clopidogrel

(a) omit:

(b) insert in numerical order following existing text:

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.